CDK4 and breast cancer: Due to a lack of a control treatment arm, this study could not assess the treatment effect with PIK3CA. Still, these findings suggest PIK3CA mutations may act as a prognostic biomarker for advanced breast cancer patients receiving treatment with CDK4/6 inhibitors.